Core Viewpoint - The market anticipates Inovio Pharmaceuticals (INO) to report a year-over-year increase in earnings despite lower revenues when it releases its quarterly results for June 2025 [1] Earnings Expectations - Inovio is expected to report a quarterly loss of $0.63 per share, reflecting a year-over-year change of +47.1% [3] - Revenues are projected to be $0.05 million, down 50% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 4.55% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for Inovio is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +10.76% [11] Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [9] - Inovio currently holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [11] Historical Performance - Inovio has beaten consensus EPS estimates three times over the last four quarters [13] - In the last reported quarter, Inovio was expected to post a loss of $0.74 per share but actually reported a loss of -$0.51, resulting in a surprise of +31.08% [12] Industry Context - Another company in the biomedical sector, VistaGen Therapeutics, is expected to report a loss of $0.47 per share, indicating a year-over-year change of -34.3% [17] - VistaGen's revenues are expected to be $0.65 million, up 712.5% from the previous year [17]

Core Viewpoint - INOVIO Pharmaceuticals, Inc. has announced a public offering of 14,285,715 shares of common stock and accompanying Series A and Series B warrants, priced at $1.75 per share, aiming to raise approximately $25 million before expenses [1][2]. Group 1: Offering Details - The public offering includes 14,285,715 shares of common stock and warrants to purchase an equal number of shares at an exercise price of $1.75 [1]. - The offering is expected to close on or about July 7, 2025, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase up to 2,142,857 additional shares and warrants at the public offering price [1]. Group 2: Financial Aspects - Gross proceeds from the offering are anticipated to be approximately $25 million, excluding underwriting discounts and commissions [2]. - The offering is being managed by Piper Sandler & Co. as the sole active book-running manager, with Oppenheimer & Co. Inc. as a passive bookrunner [2]. Group 3: Regulatory Information - A shelf registration statement for the offering was filed with the SEC on November 9, 2023, and was declared effective on January 31, 2024 [3]. - The offering is conducted through a written prospectus and prospectus supplement available on the SEC's website [3]. Group 4: Company Overview - INOVIO is focused on developing and commercializing DNA medicines aimed at treating HPV-related diseases, cancer, and infectious diseases [5]. - The company's technology is designed to optimize the design and delivery of DNA medicines that enable the body to produce its own disease-fighting tools [5].

Financial Performance - Inovio Pharmaceuticals reported a quarterly loss of $0.51 per share, better than the Zacks Consensus Estimate of a loss of $0.74, and an improvement from a loss of $1.31 per share a year ago, representing an earnings surprise of 31.08% [1] - The company posted revenues of $0.07 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 30%, compared to zero revenues a year ago [2] Stock Performance - Inovio shares have increased by approximately 6% since the beginning of the year, while the S&P 500 has declined by 0.6% [3] - The current Zacks Rank for Inovio is 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.60 on revenues of $0.05 million, and for the current fiscal year, it is -$2.27 on revenues of $7.7 million [7] - The Medical - Biomedical and Genetics industry, to which Inovio belongs, is currently in the top 35% of Zacks industries, suggesting a favorable outlook for stocks within this sector [8]

Financial Data and Key Metrics Changes - Inovio reported a net loss of $19.7 million or $0.51 per share for Q1 2025, compared to a net loss of $30.5 million or $1.31 per share for Q1 2024, indicating a significant improvement in financial performance [25] - Operating expenses decreased from $31.5 million in Q1 2024 to $25.1 million in Q1 2025, representing a 20% reduction [25] - The company ended Q1 2025 with $68.4 million in cash and short-term investments, down from $94.1 million at the end of 2024, with an estimated cash runway into Q1 2026 [25] Business Line Data and Key Metrics Changes - The primary focus remains on the submission of the Biologics License Application (BLA) for INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP) [6][14] - The company resolved manufacturing issues related to the Selectra device and initiated device design verification testing, which is crucial for BLA submissions [7][10] Market Data and Key Metrics Changes - RRP is a rare HPV-related disease affecting approximately 14,000 people in the US, with ongoing market research indicating a significant need for non-surgical treatment options [16][17] - The current standard of care involves multiple surgeries, which do not address the underlying disease, highlighting the potential market opportunity for INO-3107 [17][18] Company Strategy and Development Direction - Inovio aims to submit the BLA for INO-3107 by mid-2025, with a goal of receiving FDA acceptance by the end of the year and a potential PDUFA date in mid-2026 [6][14] - The company is also advancing its DNA encoded monoclonal antibody (dMAb) technology, which could offer significant advantages over traditional monoclonal antibody production methods [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of INO-3107 to change the treatment paradigm for RRP, emphasizing the importance of reducing the number of surgeries for patients [6][74] - The company is focused on maintaining or improving clinical benefits seen to date and plans to submit a proposed protocol for a supplemental BLA in the future [15] Other Important Information - Inovio has been actively engaging with the RRP community and presenting data at scientific conferences to raise awareness of INO-3107 [11][12] - The company is refining its go-to-market model and planning further build-out of its commercial organization [19] Q&A Session Summary Question: Additional details on the COSM presentation - Management confirmed that the focus will be on surgery counts and additional data will be submitted for peer review [28][29] Question: Number of MSLs to onboard and epidemiology data - Management acknowledged that the 14,000 figure is likely an underestimate and ongoing research is being conducted to refine this number [31][32] Question: Expectation for surgery sparing claim in the label - Management indicated that while it is too early to predict FDA terminology, the clinical benefit of reduced surgeries is clear [38][39] Question: Update on registrational strategy outside the US - Management confirmed that discussions with European regulators are ongoing and aligned with trial design expectations [40] Question: Initial indication for dMAb technology - Management stated that while specific indications are not disclosed, the technology has broad applications beyond monoclonal antibodies [42] Question: Priority review status concerns - Management expressed confidence that the unique benefits of INO-3107 would support its case for accelerated approval despite potential competition [46][47] Question: Plans to add more data to the filing - Management confirmed that the clinical package is complete and ready for submission [48][50] Question: Pricing considerations for the initial treatment regimen - Management indicated that pricing discussions have been favorable, with comparisons to similar products in the rare disease space [56][57] Question: Plans for disclosing baseline characteristics in the confirmatory trial - Management confirmed that the patient population will be representative of the normal RRP population, focusing on HPV serotypes [69][70]

Financial Data and Key Metrics Changes - Operating expenses decreased from $31.5 million in Q1 2024 to $25.1 million in Q1 2025, representing a 20% reduction [24] - Net loss for Q1 2025 was $19.7 million or $0.51 per share, compared to a net loss of $30.5 million or $1.31 per share in Q1 2024 [24] - Cash, cash equivalents, and short-term investments at the end of Q1 2025 were $68.4 million, down from $94.1 million at the end of 2024, with an estimated cash runway into Q1 2026 [24] Business Line Data and Key Metrics Changes - The primary focus remains on the submission of the Biologics License Application (BLA) for INO-3107, targeting recurrent respiratory papillomatosis (RRP) [5][6] - Significant progress was made in resolving manufacturing issues related to the Selectra device, with device design verification testing initiated [6][9] Market Data and Key Metrics Changes - RRP affects approximately 14,000 people in the US, with ongoing research suggesting this number may be an underestimate [15][30] - The current standard of care for RRP is surgery, which does not address the underlying disease, highlighting the urgent need for non-surgical treatment options [16] Company Strategy and Development Direction - The company aims to submit the BLA for INO-3107 by mid-2025, with a goal of receiving FDA acceptance by the end of the year [5][13] - The strategy includes leveraging market research insights to position INO-3107 as a preferred treatment option for patients and healthcare providers [7][18] - The company is also advancing its DNA encoded monoclonal antibody (dMAb) technology, which has shown promising interim results in clinical trials [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of INO-3107 to change the treatment paradigm for RRP, emphasizing the importance of each surgery to patients [73] - The company is focused on maintaining or improving clinical benefits seen to date and plans to submit a proposed protocol for a supplemental BLA in the future [14] Other Important Information - The company has been actively engaging with the RRP community and presenting data at scientific conferences to raise awareness of INO-3107 [10][11] - The dMAb technology is being explored for various disease targets, with initial proof of concept data showing durable antibody production [21][22] Q&A Session Summary Question: Details on the COSM presentation - The presentation will focus on surgery counts and additional data will be submitted for peer review [27][29] Question: Number of MSLs to onboard and epidemiology data - The company is conducting research to update the 14,000 active cases figure, which is believed to be an underestimate [30][31] Question: Expectation for surgery sparing claims and competitive differentiation - The FDA recognizes the clinical benefit of reduced surgeries, and the company believes it has a solid rationale for accelerated approval despite potential competition [36][46] Question: Plans for additional data in the filing package - The clinical package has been strengthened with detailed immunology characterization and durability data, and is ready for submission [48][49] Question: Pricing strategy and commercialization plans - Initial pricing is expected to be in line with other rare disease treatments, with plans to market INO-3107 in the US independently while considering partnerships for international markets [56][58] Question: Disclosure of baseline characteristics for the confirmatory trial - The patient population will be representative of the normal RRP population, with a focus on HPV serotypes [66][69]

Financial Performance - INOVIO reported a net loss of $19.7 million, or $0.51 per share, for Q1 2025, a decrease from a net loss of $30.5 million, or $1.31 per share, in Q1 2024[10]. - Total operating expenses decreased to $25.1 million in Q1 2025 from $31.5 million in Q1 2024[10]. Research and Development - Research and Development (R&D) expenses decreased to $16.1 million in Q1 2025 from $20.9 million in Q1 2024, primarily due to lower drug manufacturing and immunology expenses[10]. - Interim results from a Phase 1 proof-of-concept trial for DNA-encoded monoclonal antibodies (DMAbs) showed 100% of participants maintained biologically relevant levels of DMAbs at week 72[7]. General and Administrative Expenses - General and Administrative (G&A) expenses decreased to $9.0 million in Q1 2025 from $10.6 million in Q1 2024, attributed to reduced legal expenses and stock-based compensation[10]. Cash Position - Cash, cash equivalents, and short-term investments were $68.4 million as of March 31, 2025, down from $94.1 million as of December 31, 2024[17]. - INOVIO's operational net cash burn is estimated at approximately $22 million for Q2 2025[12]. Future Plans - INOVIO plans to submit a Biologics License Application (BLA) for INO-3107 in mid-2025, with the goal of FDA acceptance by the end of 2025[4]. - INO-3107 has received breakthrough therapy designation from the FDA, and a priority review request is planned[4]. Share Information - As of March 31, 2025, INOVIO had 36.7 million common shares outstanding and 51.3 million on a fully diluted basis[17].

Core Insights - INOVIO is on track to submit its Biologics License Application (BLA) for INO-3107, a treatment for recurrent respiratory papillomatosis (RRP), in mid-2025, with the goal of FDA acceptance by the end of 2025 [2][3][7] - The company reported a decrease in net loss for Q1 2025 to $19.7 million, or $0.51 per share, compared to a net loss of $30.5 million, or $1.31 per share, in Q1 2024 [15][19] - INOVIO's cash, cash equivalents, and short-term investments were $68.4 million as of March 31, 2025, down from $94.1 million at the end of 2024, with an estimated operational net cash burn of approximately $22 million for Q2 2025 [12][15] Company Developments - INOVIO has initiated device design verification testing for the CELLECTRA device, which is required for the BLA submission, expected to be completed in the first half of 2025 [3][7] - The company is conducting ongoing market research to support its commercial readiness plans and has published clinical data from a Phase 1/2 trial in a peer-reviewed journal [4][6] - Promising interim results from a Phase 1 proof-of-concept trial for DNA-encoded monoclonal antibodies (DMAbs) were announced, with additional data to be presented at upcoming scientific meetings [6][9] Financial Performance - Research and development expenses decreased to $16.1 million in Q1 2025 from $20.9 million in Q1 2024, primarily due to lower drug manufacturing and immunology expenses [15] - General and administrative expenses also decreased to $9.0 million in Q1 2025 from $10.6 million in Q1 2024, attributed to lower legal expenses and stock-based compensation [15] - Total operating expenses for Q1 2025 were $25.1 million, down from $31.5 million in the same period of 2024 [15][19]

Financial Performance - Total revenue for Q1 2025 was $65,000, compared to $0 in Q1 2024, all derived from a collaborative arrangement with ApolloBio[148] - Research and development expenses decreased by 23% year-over-year, totaling $16.1 million in Q1 2025, down from $20.9 million in Q1 2024[150] - General and administrative expenses were $9.0 million in Q1 2025, down from $10.6 million in Q1 2024[153] - Interest income decreased to $808,000 in Q1 2025 from $1.5 million in Q1 2024, primarily due to a lower short-term investment balance[154] - The company reported an accumulated deficit of $1.7 billion as of March 31, 2025[145] - The accumulated deficit as of March 31, 2025, was $1.7 billion, with expectations to continue operating at a loss in the near term[170] Cash Flow and Financing - As of March 31, 2025, the company had cash, cash equivalents, and short-term investments totaling $68.4 million, down from $94.1 million as of December 31, 2024[159] - The net cash used in operating activities for the three months ended March 31, 2025, was $26.9 million, a decrease from $28.8 million for the same period in 2024[160] - The company reported a net cash provided by financing activities of $1.0 million for the three months ended March 31, 2025, compared to a net cash used of $11.4 million in the same period of 2024[163] - The company anticipates needing additional financing to complete the development and commercialization of its product candidates, including INO-3107[170] - During the three months ended March 31, 2025, the company sold 518,670 shares of common stock under the 2024 Sales Agreement, generating net proceeds of $1.1 million[167] Research and Development - The largest decrease in research and development expenses was $4.1 million for INO-3107, which saw a 54% reduction from $7.6 million in Q1 2024[150] - INOVIO plans to begin a rolling submission of the Biologic License Application (BLA) in mid-2025, aiming for FDA file acceptance by the end of 2025[139] - INOVIO is developing INO-3112 in collaboration with Coherus BioSciences for the treatment of HPV-positive oropharyngeal squamous cell carcinoma, with a planned Phase 3 trial[140] - The company has ceased development of a DNA medicine candidate for HPV-related cervical high-grade squamous intraepithelial lesions in the U.S., while a collaborator continues trials in China[142] Market and Investment - The change in fair value of common stock warrant liability was primarily due to a decrease in stock price during the period[155] - The company experienced an accumulated unrealized loss of $1.7 million in the market value of its investment portfolio due to rising interest rates as of March 31, 2025[175] - The company had approximately $605,000 in minimum purchase obligations related to supply agreements with contract manufacturers as of March 31, 2025[173] - The company expects its cash runway to extend into the first quarter of 2026 without further capital raising activities[170] - The company does not have material exposure to foreign currency fluctuations, primarily operating in U.S. dollars[176]

Company Overview - Inovio Pharmaceuticals is on track to potentially have the first DNA immunotherapy approved in the US, distinguishing itself from the more widely recognized mRNA therapies [1] - The company emphasizes the stability of DNA compared to mRNA, which is inherently more unstable and requires lipid nanoparticles for delivery [2] Technology Differentiation - DNA medicines utilize a proprietary delivery system called CELLECTRA, allowing for more stable distribution without the need for ultracold storage, unlike mRNA which requires frozen shipping [2] - The immune responses generated by DNA medicines differ from those of mRNA, with DNA being capable of producing a broader range of immune responses [2]

Inovio Pharmaceuticals (INO) 2025 Conference Summary Company Overview - Inovio Pharmaceuticals is on track to potentially have the first DNA immunotherapy approved in the US, differentiating itself from mRNA therapies with unique stability and delivery systems [1][2] Key Differentiators of DNA Medicines - DNA medicines are more stable than mRNA and do not require lipid nanoparticles for delivery, allowing for easier distribution without ultra-cold storage [3][4] - DNA therapies generate robust T cell responses, particularly CD8 T cells, while mRNA is more effective at producing high levels of neutralizing antibodies [3][4] - The DNA platform avoids issues related to pre-existing anti-vector immunity and flu-like adverse events commonly associated with mRNA and viral vector therapies [3][4] Clinical Data and Safety Profile - Approximately 19,000 administrations have been conducted across 6,000 subjects, showing mild tolerability with no significant differentiation from placebo adverse events [8] - The manufacturing cost of DNA medicines varies based on scale, with a focus on reducing costs for vaccine indications [9][10] RRP (Recurrent Respiratory Papillomatosis) Indication - RRP is a rare disease caused by HPV types 6 and 11, leading to wart-like growths in the respiratory tract, significantly affecting patients' quality of life [13][14] - Current standard treatment involves repeated surgeries, which can lead to permanent vocal cord damage and high economic costs [14][15] - The estimated prevalence of RRP is likely higher than the previously reported 14,000 active patients, with HPV vaccination rates remaining stagnant [16][17] BLA Submission Timeline - Inovio plans to commence rolling submission for the Biologics License Application (BLA) by mid-2025, pending completion of device testing [18][19] - A manufacturing issue related to a disposable component was identified and resolved, allowing for progress towards BLA submission [20][21] Phase 1/2 Study Results - The Phase 1/2 study showed a statistically significant reduction in surgeries from a median of four to one, with 72% of patients experiencing a 50% or greater reduction in surgeries [25][28] - Long-term data indicates continued clinical improvement, with 86% of patients showing significant improvement over a median follow-up of 2.8 years [28][29] Confirmatory Trial Design - The FDA has requested a placebo-controlled confirmatory trial to validate efficacy, with plans to expand the clinical trial site base to over 20 sites [33][35] - The trial will include a representative patient population with varying disease severity and HPV types [34] dMAb Technology - Inovio's dMAb platform demonstrated the ability to produce monoclonal antibodies against COVID-19, showing sustained production without generating anti-drug antibodies [43][44] - The technology has potential applications in protein replacement therapies, expanding its therapeutic scope [44][45] Future Programs and Financial Position - Inovio is focusing resources on advancing INO-3107 for RRP while also discussing future developments for INO-312 for oropharyngeal cancer [45][46] - The company reported a cash position of $94.1 million, providing a runway into Q1 2026 [49]